- Conditions
- Age-Related Macular Degeneration
- Interventions
- Eculizumab, Saline
- Drug
- Lead sponsor
- Philip J. Rosenfeld, MD, PhD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 997
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
- Interventions
- Losartan
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pancreatic Cancer, Advanced Cancer
- Interventions
- Hydroxychloroquine Sulfate, LY3214996
- Drug
- Lead sponsor
- Kimberly Perez, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Chapel Hill, North Carolina
- Conditions
- Immune System Disorder, Healthy Volunteers
- Interventions
- Belumosudil, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Healthy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- capmatinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- La Jolla, California • Sacramento, California • Fairfax, Virginia
- Conditions
- Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
- Interventions
- Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Lymphoproliferative Diseases
- Interventions
- GRN163L
- Drug
- Lead sponsor
- Geron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Hackensack, New Jersey • Buffalo, New York + 5 more
- Conditions
- Drinking, Alcohol, Drinking Behavior
- Interventions
- Control App Version, Standard App Version, Experimental, Feedback App Version
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 21 Years to 25 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Macular Degeneration
- Interventions
- Celecoxib
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Binge Eating, Inhibition (Psychology)
- Interventions
- Virtual-reality-based training, Inhibitory Control Training, Sham Inhibitory Control Training, Computerized training
- Other
- Lead sponsor
- Drexel University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimer's Disease
- Interventions
- LY450139, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more
- Conditions
- Coronavirus Infection, Type 2 Diabetes
- Interventions
- Linagliptin, Insulin regimen
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Renal Cell Carcinoma
- Interventions
- Axitinib
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- Omaha, Nebraska • Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Familial Cold Autoinflammatory Syndrome
- Interventions
- DFV890
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Post-acute Sequelae of COVID-19, Long COVID
- Interventions
- Valacyclovir, Celecoxib, Paxlovid, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell Carcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Retifanlimab, Tuparstobart, Verzistobart
- Procedure · Biological · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Abdominal Aortic Aneurysm
- Interventions
- Evolocumab, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neoplasm, Neoplasm Metastasis
- Interventions
- Abemaciclib, Clarithromycin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee
- Conditions
- Colorectal Cancer
- Interventions
- panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
- Biological · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- Arlington Heights, Illinois • Chicago, Illinois • Joliet, Illinois + 6 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Immunotherapy, Palliative Radiation Therapy, Spatially-fractionated Radiation Therapy
- Procedure · Other · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes
- Interventions
- Sitagliptin
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Vasculopathy
- Interventions
- alirocumab, placebo
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Down Syndrome
- Interventions
- Tofacitinib Oral Solution, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 6 Years to 22 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado